{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06072157",
            "orgStudyIdInfo": {
                "id": "AK006-001"
            },
            "organization": {
                "fullName": "Allakos Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria",
            "officialTitle": "A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Sequential, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of AK006 in Healthy Subjects and in Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria",
            "therapeuticArea": [
                "Other"
            ],
            "study": "study-to-assess-the-safety-tolerability-pharmacokinetics-and-immunogenicity-of-in-healthy-subjects-and-subjects-with-chronic-spontaneous-urticaria"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-08-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-09-09",
            "studyFirstSubmitQcDate": "2023-10-02",
            "studyFirstPostDateStruct": {
                "date": "2023-10-10",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-30",
                "type": "ESTIMATED"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Allakos Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 1, randomized, double-blind, placebo-controlled, sequential, single- and multiple-ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of intravenous (IV) infusions and a single subcutaneous (SC) injection of AK006. The study will be conducted in 4 parts: a single-ascending dose part (Part A) in healthy participants, a multiple-ascending dose part (Part B) in healthy participants with an expanded cohort (Part C) in participants with chronic spontaneous urticaria (CSU), and a single ascending dose SC injection cohort (Part D) in healthy participants."
        },
        "conditionsModule": {
            "conditions": [
                "Healthy Participants",
                "Chronic Spontaneous Urticaria"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Single (Part A) and multiple (Part B) ascending IV dose study in healthy participants with a multiple dose expansion (Part C) in participants with chronic spontaneous urticaria. Single ascending (Part D) subcutaneous (SC) dose study in healthy participants",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "maskingDescription": "Double-blind (placebo) essentially identical in appearance to the investigational drug (AK006)",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 148,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part A - Single Ascending Dose (SAD) Intravenous Cohorts",
                    "type": "EXPERIMENTAL",
                    "description": "Part A: Healthy adult participants will receive a single intravenous infusion of AK006 or matching placebo. The dose of AK006 will be increased per cohort. There will be up to 5 cohorts evaluated.",
                    "interventionNames": [
                        "Drug: AK006-IV",
                        "Drug: Placebo-IV"
                    ]
                },
                {
                    "label": "Part B - Multiple Ascending Dose (MAD) Intravenous Cohorts",
                    "type": "EXPERIMENTAL",
                    "description": "Part B: Healthy adult participants will receive multiple intravenous infusions of AK006 or matching placebo. The dose of AK006 will be increased per cohort. There will be up to 3 cohorts evaluated.",
                    "interventionNames": [
                        "Drug: AK006-IV",
                        "Drug: Placebo-IV"
                    ]
                },
                {
                    "label": "Cohort C - Multiple Dose Intravenous Cohort",
                    "type": "EXPERIMENTAL",
                    "description": "Part C: Adults with Chronic Spontaneous Urticaria will receive multiple intravenous infusions of AK006 or matching placebo.",
                    "interventionNames": [
                        "Drug: AK006-IV",
                        "Drug: Placebo-IV"
                    ]
                },
                {
                    "label": "Cohort D - Single Ascending Dose (SAD) Subcutaneous Cohorts",
                    "type": "EXPERIMENTAL",
                    "description": "Part D: Healthy adult participants will receive a single subcutaneous injection of AK006 or matching placebo. The dose of AK006 will be increased per cohort. There will be up to 2 cohorts evaluated.",
                    "interventionNames": [
                        "Drug: AK006-SC",
                        "Drug: Placebo-SC"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "AK006-IV",
                    "description": "Intravenous infusion",
                    "armGroupLabels": [
                        "Cohort C - Multiple Dose Intravenous Cohort",
                        "Part A - Single Ascending Dose (SAD) Intravenous Cohorts",
                        "Part B - Multiple Ascending Dose (MAD) Intravenous Cohorts"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo-IV",
                    "description": "Intravenous infusion",
                    "armGroupLabels": [
                        "Cohort C - Multiple Dose Intravenous Cohort",
                        "Part A - Single Ascending Dose (SAD) Intravenous Cohorts",
                        "Part B - Multiple Ascending Dose (MAD) Intravenous Cohorts"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "AK006-SC",
                    "description": "Subcutaneous",
                    "armGroupLabels": [
                        "Cohort D - Single Ascending Dose (SAD) Subcutaneous Cohorts"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo-SC",
                    "description": "Subcutaneous",
                    "armGroupLabels": [
                        "Cohort D - Single Ascending Dose (SAD) Subcutaneous Cohorts"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence and severity of adverse events (AEs)",
                    "description": "AEs, serious AEs, and treatment emergent AEs (AE that starts after start of investigational product)",
                    "timeFrame": "Screening to Day 113 (Part A and D), Screening to Day 141 (Part B), and Screening to Day 197 (Part C)"
                },
                {
                    "measure": "Incidence of AEs of special interest",
                    "description": "Infusion-related reactions, injection-related reactions, injection site reactions, anaphylaxis, and opportunistic infections",
                    "timeFrame": "Day 1 to Day 113 (Part A and D), Day 1 to Day 141 (Part B), and Day 1 to Day 197 (Part C)"
                },
                {
                    "measure": "AEs leading to discontinuation",
                    "description": "AEs",
                    "timeFrame": "Day 1 to Day 113 (Part A and D), Day 1 to Day 141 (Part B), and Day 1 to Day 197 (Part C)"
                },
                {
                    "measure": "Incidence of clinically significant abnormal laboratory values, electrocardiograms (ECGs), and vital signs",
                    "description": "Incidence of clinically significant abnormal laboratory values, electrocardiograms (ECGs), and vital signs",
                    "timeFrame": "Day 1 to Day 113 (Part A and D), Day 1 to Day 141 (Part B), and Day 1 to Day 197 (Part C)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "AK006 serum concentration at end of IV infusion",
                    "description": "AK006 Serum concentration (ng/mL) at end of infusion",
                    "timeFrame": "Day 1 (Part A) and Day 29 (Part B)"
                },
                {
                    "measure": "AK006 area under the concentration-time curve (AUC) from time 0 to the time of last quantifiable concentration (AUC[0-last])",
                    "description": "AK006 AUC(0-last) (ng x h/mL)",
                    "timeFrame": "Day 1 to Day 113 (Part A and D) and Day 29 to Day 141 (Part B)"
                },
                {
                    "measure": "AK006 AUC from time 0 extrapolated to infinity (AUC[0-inf])",
                    "description": "AK006 AUC(0-inf) (ng x h/mL)",
                    "timeFrame": "Day 1 to Day 113 (Part A and D)"
                },
                {
                    "measure": "Total systemic clearance of AK006 after intravenous or subcutaneous dose (CL)",
                    "description": "AK006 CL (L/h/kg)",
                    "timeFrame": "Day 1 to Day 113 (Part A and D) and Day 1 to Day 141 (Part B)"
                },
                {
                    "measure": "Systemic steady-state volume of distribution (Vss) of AK006",
                    "description": "AK006 Vss (mg/L)",
                    "timeFrame": "Day 1 to Day 113 (Part A and D) and Day 1 to Day 141 (Part B)"
                },
                {
                    "measure": "AK006 Terminal elimination phase half-life (t1/2)",
                    "description": "AK006 t1/2 (hours)",
                    "timeFrame": "Day 1 to Day 113 (Part A and D) and Day 1 to Day 141 (Part B)"
                },
                {
                    "measure": "Predose AK006 serum concentration (Ctrough, before the next dose) (Part B)",
                    "description": "AK006 Ctrough (ng/mL)",
                    "timeFrame": "Day 29 (pre-dose)"
                },
                {
                    "measure": "AK006 AUC(0-last) after the second dose (Part B)",
                    "description": "AK006 AUC(0-last) (ng x h/mL)",
                    "timeFrame": "Day 29 to Day 141"
                },
                {
                    "measure": "AK006 AUC over the dosing time interval (time 0 to 28 days) (AUC[tau]) (Part B)",
                    "description": "AK006 AUC(tau) (ng x h/mL)",
                    "timeFrame": "Day 1 to Day 28 with each dosing interval"
                },
                {
                    "measure": "AK006 serum concentrations",
                    "description": "AK006 ng/mL",
                    "timeFrame": "Day 1 to Day 141"
                },
                {
                    "measure": "AK006 absolute bioavailability subcutaneous injection",
                    "description": "Ratio of mean AUC(0-last) after subcutaneous injection to mean AUC(0-last) after intravenous administration adjusted for dose",
                    "timeFrame": "Day 1 to Day 113 (Part A and D)"
                },
                {
                    "measure": "AK006 PK dose proportionality (Part A, B, D)",
                    "description": "Comparing dose-normalized Cmax and AUC (Part A, B, and D)",
                    "timeFrame": "Up to Day 141"
                },
                {
                    "measure": "AK006 PK dose stationarity (Part B)",
                    "description": "Comparing AUCtau from last dose to AUCtau from first dose",
                    "timeFrame": "Up to Day 141"
                },
                {
                    "measure": "AK006 Anti-drug Antibodies (ADAs)",
                    "description": "Number of participants with positive or negative AK006-ADAs",
                    "timeFrame": "Day 1 to Day 113 (Part A and D), Day 1 to Day 141 (Part B) and Day 1 to Day 197 (Part C)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\nTo be included in the study, the participant must:\n\n* Weigh between 60 and 120 kg (inclusive) and have a body mass index (BMI) between 20 and 32 kg/m2, inclusive\n* Agree (female of childbearing potential or male with female partner of childbearing potential) to use a highly effective method (\\<1% failure rate) of birth control, if sexually active from screening and for 16 weeks after the last dose of investigational product (IP).\n\nAdditionally, to be included in Part A, B and D, the participant must:\n\n\u2022 Be in good general health with no significant medical history and has no clinically significant abnormalities on physical examination\n\nAdditionally, to be included in Part C, the participant must:\n\n* Have a diagnosis of chronic spontaneous urticaria (CSU) for at least 6 months prior to screening\n* Has a diagnosis of moderate to severe CSU that is refractory to stable doses of a single 2nd or later generation H1-AH between 1\u00d7 and 4\u00d7 the licensed dose and frequency at the time of randomization as defined by the following:\n\n  * Presence of hives and itch for \u22656 consecutive weeks at any time prior to the Screening, despite the use of non-sedating H1-AHs. Note: Subject must be on a non-sedating H1-AH for treatment of CSU symptoms at the time of the Screening visit.\n  * UAS7 score \u226516 with a HSS7 score \u22658 for the 2 consecutive weeks prior to randomization (Day 1) while on the stable dose of an H1-AH.\n* Be on a stable dose of a single 2nd or later generation H1-antihistamines for the treatment of CSU, between 1\u00d7 and 4\u00d7 the licensed dose and frequency, by Day -14 of the Screening Period and must be willing to remain on the same stable dose throughout the study.\n* Able and willing to complete a daily electronic diary to collect CSU symptoms for the duration of the study.\n\nKey Exclusion Criteria:\n\nA participant who meets any of the following exclusion criteria will not be eligible for inclusion in the study:\n\n* Female participants who are pregnant, lactating, or planning to become pregnant during the study.\n* Abnormal laboratory values, or findings in physical examination, ECG (QTc \\>450 ms for males and \\>470 ms for females), or vital signs considered to be clinically significant by the investigator.\n\nAdditionally, a participant will be excluded from Part A, B and D, if:\n\n\u2022 Received treatment with any prescribed (excluding hormonal contraceptives or hormone replacement therapy \\[post-menopausal females\\]) or nonprescribed systemic or topical medication (including herbal product, and vitamins) within 21 days prior to the first dose of IP (excluding acetaminophen).\n\nAdditionally, a participant will be excluded from Part C, if:\n\n* Has known or suspected urticarial vasculitis\n* Subject has causes other than CSU for their urticaria including symptomatic dermographism, cholinergic urticaria, or any inducible urticaria\n* Subject has other conditions or diseases that in the investigator's opinion might influence study evaluations and results\n* Has any disease or condition (medical or surgical) which, in the opinion of the investigator, or medical monitor, would place the subject at increased risk",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "AK006 Study Team",
                    "role": "CONTACT",
                    "phone": "650-542-0421",
                    "email": "AK006ClinicalStudies@allakos.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Chin Lee, MD",
                    "affiliation": "Allakos Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Site 601-001 Healthy Volunteer Clinical Research Unit (Part A, B and D)",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Anniston",
                    "state": "Alabama",
                    "zip": "36207",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.65983,
                        "lon": -85.83163
                    }
                },
                {
                    "facility": "Site 601-004 (Part C)",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35209",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "Site 601-008 (Part C)",
                    "status": "RECRUITING",
                    "city": "Scottsdale",
                    "state": "Arizona",
                    "zip": "85251",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.50921,
                        "lon": -111.89903
                    }
                },
                {
                    "facility": "Site 601-014 (Part C)",
                    "status": "RECRUITING",
                    "city": "Bakersfield",
                    "state": "California",
                    "zip": "93301",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.37329,
                        "lon": -119.01871
                    }
                },
                {
                    "facility": "Site 601-007 (Part C)",
                    "status": "RECRUITING",
                    "city": "Encino",
                    "state": "California",
                    "zip": "91436",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.15917,
                        "lon": -118.50119
                    }
                },
                {
                    "facility": "Site 601-015 (Part C)",
                    "status": "RECRUITING",
                    "city": "Upland",
                    "state": "California",
                    "zip": "91786",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.09751,
                        "lon": -117.64839
                    }
                },
                {
                    "facility": "Site 601-016 (Part C)",
                    "status": "RECRUITING",
                    "city": "Colorado Springs",
                    "state": "Colorado",
                    "zip": "80907",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.83388,
                        "lon": -104.82136
                    }
                },
                {
                    "facility": "Site 601-006 (Part C)",
                    "status": "RECRUITING",
                    "city": "Overland Park",
                    "state": "Kansas",
                    "zip": "66211",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.98223,
                        "lon": -94.67079
                    }
                },
                {
                    "facility": "Site 601-019 (Part C)",
                    "status": "RECRUITING",
                    "city": "Lexington",
                    "state": "Kentucky",
                    "zip": "40509",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.98869,
                        "lon": -84.47772
                    }
                },
                {
                    "facility": "Site 601-012 (Part C)",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02111",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Site 601-023 (Part C)",
                    "status": "RECRUITING",
                    "city": "Troy",
                    "state": "Michigan",
                    "zip": "48084",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.60559,
                        "lon": -83.14993
                    }
                },
                {
                    "facility": "Site 601-011 (Part C)",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63141",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Site 601-020 (Part C)",
                    "status": "RECRUITING",
                    "city": "Brooklyn",
                    "state": "New York",
                    "zip": "11203",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.6501,
                        "lon": -73.94958
                    }
                },
                {
                    "facility": "Site 601-017 (Part C)",
                    "status": "RECRUITING",
                    "city": "Fargo",
                    "state": "North Dakota",
                    "zip": "58103",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 46.87719,
                        "lon": -96.7898
                    }
                },
                {
                    "facility": "Site 601-002 (Part C)",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45236",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "Site 601-018 (Part C)",
                    "status": "RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97201",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Site 601-010 (Part C)",
                    "status": "RECRUITING",
                    "city": "El Paso",
                    "state": "Texas",
                    "zip": "79912",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 31.75872,
                        "lon": -106.48693
                    }
                },
                {
                    "facility": "Site 601-013 (Part C)",
                    "status": "RECRUITING",
                    "city": "Greenfield",
                    "state": "Wisconsin",
                    "zip": "53228",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.9614,
                        "lon": -88.01259
                    }
                },
                {
                    "facility": "Site 601-106 (Part C)",
                    "status": "RECRUITING",
                    "city": "Calgary",
                    "state": "Alberta",
                    "zip": "T2M 1A6",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.05011,
                        "lon": -114.08529
                    }
                },
                {
                    "facility": "Site 601-103 (Part C)",
                    "status": "RECRUITING",
                    "city": "London",
                    "state": "Ontario",
                    "zip": "N6H 5L5",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.98339,
                        "lon": -81.23304
                    }
                },
                {
                    "facility": "Site 601-107 (Part C)",
                    "status": "RECRUITING",
                    "city": "Niagara Falls",
                    "state": "Ontario",
                    "zip": "L2H 1H5",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.10012,
                        "lon": -79.06627
                    }
                },
                {
                    "facility": "Site 601-108 (Part C)",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 1E2",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Site 601-102 (Part C)",
                    "status": "RECRUITING",
                    "city": "Qu\u00e9bec",
                    "state": "Quebec",
                    "zip": "G1V 4W2",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 46.81228,
                        "lon": -71.21454
                    }
                },
                {
                    "facility": "Site 601-105 (Part C)",
                    "status": "RECRUITING",
                    "city": "Qu\u00e9bec",
                    "state": "Quebec",
                    "zip": "G1W 4R4",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "AK006 Clinical Study Team",
                            "role": "CONTACT",
                            "phone": "650-542-0421",
                            "email": "AK006ClinicalStudies@allakos.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 46.81228,
                        "lon": -71.21454
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "37413923",
                    "type": "BACKGROUND",
                    "citation": "O'Sullivan JA, Youngblood BA, Schleimer RP, Bochner BS. Siglecs as potential targets of therapy in human mast cell- and/or eosinophil-associated diseases. Semin Immunol. 2023 Sep;69:101799. doi: 10.1016/j.smim.2023.101799. Epub 2023 Jul 4."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000014581",
                    "term": "Urticaria"
                },
                {
                    "id": "D000080223",
                    "term": "Chronic Urticaria"
                }
            ],
            "ancestors": [
                {
                    "id": "D000017445",
                    "term": "Skin Diseases, Vascular"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000006969",
                    "term": "Hypersensitivity, Immediate"
                },
                {
                    "id": "D000006967",
                    "term": "Hypersensitivity"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000002908",
                    "term": "Chronic Disease"
                },
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M17330",
                    "name": "Urticaria",
                    "asFound": "Urticaria",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2129",
                    "name": "Chronic Urticaria",
                    "asFound": "Chronic Spontaneous Urticaria",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M19714",
                    "name": "Skin Diseases, Vascular",
                    "relevance": "LOW"
                },
                {
                    "id": "M10018",
                    "name": "Hypersensitivity",
                    "relevance": "LOW"
                },
                {
                    "id": "M10020",
                    "name": "Hypersensitivity, Immediate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6147",
                    "name": "Chronic Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M9709",
                    "name": "Histamine Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M9710",
                    "name": "Histamine H1 Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}